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Abstract
The endocannabinoid system has been implicated in the modulation of adult neurogenesis. Here, we describe the effect of
type 1 cannabinoid receptor (CB1R) activation on self-renewal, proliferation and neuronal differentiation in mouse neonatal
subventricular zone (SVZ) stem/progenitor cell cultures. Expression of CB1R was detected in SVZ-derived immature cells
(Nestin-positive), neurons and astrocytes. Stimulation of the CB1R by (R)-(+)-Methanandamide (R-m-AEA) increased self-
renewal of SVZ cells, as assessed by counting the number of secondary neurospheres and the number of Sox2+/+ cell pairs,
an effect blocked by Notch pathway inhibition. Moreover, R-m-AEA treatment for 48 h, increased proliferation as assessed
by BrdU incorporation assay, an effect mediated by activation of MAPK-ERK and AKT pathways. Surprisingly, stimulation of
CB1R by R-m-AEA also promoted neuronal differentiation (without affecting glial differentiation), at 7 days, as shown by
counting the number of NeuN-positive neurons in the cultures. Moreover, by monitoring intracellular calcium
concentrations ([Ca2+]i) in single cells following KCl and histamine stimuli, a method that allows the functional evaluation
of neuronal differentiation, we observed an increase in neuronal-like cells. This proneurogenic effect was blocked when SVZ
cells were co-incubated with R-m-AEA and the CB1R antagonist AM 251, for 7 days, thus indicating that this effect involves
CB1R activation. In accordance with an effect on neuronal differentiation and maturation, R-m-AEA also increased neurite
growth, as evaluated by quantifying and measuring the number of MAP2-positive processes. Taken together, these results
demonstrate that CB1R activation induces proliferation, self-renewal and neuronal differentiation from mouse neonatal SVZ
cell cultures.
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Introduction
In the adult brain, the SVZ is endowed with neural stem cells
that give rise to highly proliferating progenitor cells, able to
differentiate into neurons and glial cells [1,2]. In vivo, the
progenitors undergo cell death [3] or originate neuroblasts that
migrate tangentially along the rostral migratory stream (RMS)
towards the olfactory bulb [4] where they become functional and
integrate into pre-established brain circuits [5]. In addition, in a
different perspective, brain injuries, such as seizures, head traumas
and stroke, result in stimulation of neurogenesis, and this has been
proposed as an endogenous attempt to repair and reduce brain
damage [6]. In fact, newly generated cells migrate out of the SVZ
towards the damaged areas upon several brain injuries and
neurodegenerative diseases [7,8]. Therefore, these proliferative
and multipotent cells may represent a potential source of neurons
and glia for brain repair, through the recruitment from the
endogenous niches or through transplantation strategies [9,10].
Although the knowledge regarding neurogenesis is increasing,
the factors available at stem cell niches that may regulate cell
proliferation, differentiation, survival, maturation and integration
remain poorly understood. Deciphering the molecular mecha-
nisms controlling these events will contribute to the development
of new strategies to treat brain diseases.
There is an emerging consensus that endocannabinoid signaling
plays a major role in adult neurogenesis. Cannabinoids act on at
least two types of receptors, the type 1 and type 2 cannabinoid
receptors (CB1R and CB2R), which are, respectively, predomi-
nantly distributed in the central nervous system (CNS) and
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immune system, although some studies have described the
presence of low levels of CB2R in the brain [11,12]. In the brain,
CB1R are targeted by endogenous cannabinoids (or endocanna-
binoids) such as anandamide (AEA) and 2-arachidonylglycerol (2-
AG), which are molecules generated by the cleavage of plasma
membrane lipid precursors, a reaction tightly controlled by
neuronal activity [13]. Once generated, endocannabinoids act
retrogradely through presynaptic CB1R, blunting membrane
depolarization and inhibiting neurotransmitter release [13].
Collectively, CB1R agonists render neurons less excitable and
thus promote neuroprotection [14]. The endocannabinoid system
has been proposed to play important roles in many pathophys-
iological processes such as Parkinson’s disease, Alzheimer’s
disease, depression, inflammation, neuropathic pain and obesity
[15,16].
Several reports have demonstrated the modulation of neural
stem cell proliferation in culture and/or in adult mice via CB1R
and CB2R activation [17–23]. Additionally, in vivo studies showed
that excitotoxicity-induced hippocampal neural progenitors pro-
liferation and neurogenesis are abolished in CB1R-knockout (KO)
mice and in wild-type (WT) mice administered with a selective
CB1R antagonist [24]. Moreover, cannabinoid receptor activation
was found to promote migration of SVZ-derived neuroblasts [25].
Although recent data have highlighted the importance of
endocannabinoids in neurogenesis, available studies in the field
mostly addressed proliferation and did not analyse their influence
on stem cell properties and neuronal differentiation. Therefore, we
have dissected the effects of the agonist (R)-(+)-Methanandamide
(R-m-AEA) on stem cell dynamic, proliferation, cell death, and
progenitor’s neuronal differentiation in mouse SVZ cultures. Our
data clearly show that CB1R activation has a proneurogenic effect
on SVZ cells, suggesting that this pathway may be modulated in
order to activate neurogenesis in SVZ cells.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with the
European Community (86/609/EEC; 2010/63/EU) guidelines
for the care and use of laboratory animals. The work was
performed with biological material obtained from mouse pups and
subsequently maintained in vitro. The study was approved by the
internal institutional ethic committee of the animal house (Biote´rio
FMUC; License nu520.000.000.2006, from the Portuguese animal
welfare authorities) after approval of the research project POCTI/
SAU-NEU 68465/2006. Sara Xapelli is a Competent Authorised
Person (Scientist- FELASA-CAT.C) for handling and conducting
laboratory animals in scientific research. The pups were handled
according to standard and humanitarian procedures to reduce
animal suffering. The animals were sacrificed by decapitation and
the brains immediately removed. Both WT C57BL6 and
transgenic mice expressing the green fluorescent protein
(C57BL/6-Tg(CAG-EGFP)1Osb/J, Jackson Laboratories, Maine,
USA) were used.
SVZ Cell Cultures
SVZ neurospheres were prepared from 1- to 3-day-old C57BL/
6 mice in serum-free medium (SFM) supplemented with 10 ng/ml
epidermal growth factor and 5 ng/ml fibroblast growth factor-2
(EGF and FGF-2; Invitrogen, Carlsbad, CA, USA), as described
previously [26] (see Supporting Information). In fact, these
conditions are optimal for the selection of stem/progenitor cells
from SVZ tissue [27–29]. Using this protocol, obtained neuro-
spheres are composed of undifferentiated cells expressing Sox2
and Nestin (Fig. S1). Six days after plating, the resulting SVZ
neurospheres were seeded onto glass coverslips coated with
0.1 mg/ml poly-D-lysine in SFM medium devoid of growth
Table 1. Primary antibodies used for immunocytochemistry.
Antigen Company Catalog number Host Clonality Dilution
CB1R Proteimax (Cotia, Brazil) PROTX07 rabbit polyclonal 1:200
Glial fibrillary acidic protein
(GFAP)
Cell Signaling Technology (Danvers, MA, USA) 3670 Mouse Monoclonal 1:500
Microtubule-associated
protein 2 (MAP2)
Sigma-Aldrich (St Louis, MO, USA) M4403 Mouse monoclonal 1:200
Doublecortin (DCX) Santa Cruz Antibodies, Santa Cruz, CA, USA) sc-8066 Goat polyclonal 1:200
Nestin Abcam (Cambridge, UK) ab6142 Mouse monoclonal 1:200
BrdU linked to IgG-labeled
Alexa fluor 594
Invitrogen (Invitrogen, Carlsbad, CA, USA) A21304 Mouse monoclonal 1:100
BrdU AbD serotec (Oxford, UK) OBT0030 Rat monoclonal 1:50
bIII tubulin Cell Signaling Technology 4466 Mouse monoclonal 1:500
Vesicular GABA Transporter
(VGAT)
Synaptic Systems (Goettingen, Germany) 131011 Mouse monoclonal 1:200
Neuronal Nuclei (NeuN) Millipore (Billerica, MA, USA) MAB377 Mouse monoclonal 1:100
anti-Tyrosine Hydroxylase
(TH)
Abcam (Cambridge, UK) AB112 Rabbit polyclonal 1:100
Olig2 Millipore AB9610 Rabbit polyclonal 1:200
Sox2 Santa Cruz Antibodies sc-17320 Goat polyclonal 1:600
Polysialylated neuronal
cell adhesion molecule
(PSA-NCAM)
Millipore MAB5324 Mouse monoclonal 1:200
doi:10.1371/journal.pone.0063529.t001
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factors. Two days after plating, the medium was renewed with or
without (control) a range of concentrations for CB1R ligands.
Pharmacological Treatments
To investigate the effect of R-m-AEA [(R)-N-(2-Hydroxy-1-
methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide] (CB1R agonist;
Tocris, Ellisville, MO, USA) on cell proliferation, neurospheres
plated as aforementioned were allowed to develop for 48 h in the
absence (control) or in the presence of R-m-AEA (100 nM,
300 nM or 1 mM) and 10 mM of 5-bromo-2-deoxyuridine (BrdU)
(Sigma-Aldrich, St Louis, MO, USA) was added for the last 4 h of
the culture session. To investigate the influence of R-m-AEA on
differentiation, neurospheres were allowed to develop for 7 days in
the absence (control) or in the presence of R-m-AEA (100 nM,
300 nM or 1 mM) and/or CB1R antagonist AM 251 [N-
(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
1H-pyrazole-3-carboxamide] (1 mM, Tocris). Neuronal differenti-
ation of proliferating progenitors was assessed in SVZ cells
dissociated from neurospheres and plated at a density of 50000
cells/cm2 onto poly-D-lysine coated glass coverslips in SFM for
48 h. The cultures were incubated in the absence (control) or in
the presence of 1 mM R-mAEA together with 10 mM BrdU for
24 h. Then the cells were washed and incubated with only R-m-
AEA for more 6 days, fixed and stained for a marker of mature
neurons (neuronal nuclear protein, NeuN) and BrdU.
To study the influence of R-m-AEA on neuritogenesis, SVZ
neurospheres obtained from WT and GFP transgenic newborn
mice were dissociated (Neurocult dissociation kit, Stemcell
Technologies Inc., Grenoble, France) and plated onto poly-D-
lysine coated glass coverslips (95% WT and 5% GFP), in SFM
devoid of growth factors at a density of 50000 cells/cm2. With this
strategy we could differentiate high-density SVZ cells endowed
with isolated GFP-positive cells. The cells were allowed to develop
for 7 days in the absence (control) or in the presence of 1 mM R-
m-AEA, and were then fixed and stained for microtubule-
associated protein 2 (MAP2).
To access whether (R)-(+)-Methanandamide promotes trimethy-
lation of histone H3 lysine 36 (H3K36m3) on the promoter region
of Neurogenin1 (Ngn1), cells were incubated with 1 mM (R)-(+)-
Methanandamide for 6 h and 24 h, and then processed for
quantitative chromatin immunoprecipitation (qChIP) (see Meth-
ods S1). To confirm qChIP analysis, the levels of Ngn1 mRNA
were determined by quantitative real time polymerase chain
reaction (qRT-PCR) in SVZ cells treated or not (control) with
1 mM R-m-AEA for 3 days (see Methods S1).
Figure 1. SVZ cells express CB1R. A: Detection of CB1R by Western blotting in SVZ. Lane 1 corresponds to SVZ proliferating cells, lane 2 to SVZ
extract from adult C57Bl6 mice and lane 3 to the negative control (total proteins from CB1R-KO mice). B–F: Representative confocal digital images
depicting CB1R immunoreactivity in SVZ cells after 7 days of differentiation [CB1R (in red); nestin (in green), GFAP (in green), PSA-NCAM (in green),
DCX (in green), bIII tubulin (in green), MAP2 (in green) and Hoechst 33342 (used to visualize cell nuclei, in blue)]. c1, e1 and f1 are magnifications of
squares in C, E and F, respectively. Scale bars = 20 mm. SVZ: subventricular zone; GFAP: Glial fibrillary acidic protein; PSA-NCAM: Polysialylated neural
cell adhesion; bIII tubulin: Neuron-specific class III beta-tubulin; MAP2: Microtubule-associated protein 2; CB1R: CB1 receptor.
doi:10.1371/journal.pone.0063529.g001
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Figure 2. (R)-(+)-Methanandamide promotes self-renewal. A: Experimental protocol. B: Bar graphs represent the number of primary and
secondary neurospheres. Data are expressed as mean6 SEM. N= 6. *P,0.05, **P,0.01 and ***P,0.001 using Dunnett’s multiple comparison test, for
comparison with control; ###P,0.001 using Dunnett’s multiple comparison test, for comparison with R-m-AEA. C: Protocol used for studying cell-
Type 1 Cannabinoid Receptors in SVZ Neurogenesis
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Self-renewal and Multipotency Assay
Self-renewal assays were performed on SVZ cells seeded at
clonal density, at 2500 cells per well in 24-well cell culture plates in
SFM containing 5 ng/ml EGF and 2.5 ng/ml FGF-2 (low EGF/
FGF-2) and supplemented or not (control) with 1 mM R-m-AEA
and/or 10 mM DAPT (a c-secretase inhibitor and therefore an
inhibitor of Notch pathway). After 6 days, the number of primary
neurospheres was determined. Then, neurospheres were collected,
dissociated as single cells (Neurocult dissociation kit) and seeded in
low EGF/FGF-2 medium as aforementioned. After 6 days, the
number of secondary neurospheres was counted. Then the
neurospheres were adhered to SuperFrost Plus glass slides
(Thermo Scientific, Menzel GmbH & Co KG, Braunscheweig,
Germany) by cytocentrifugation (3606g, 5 min; Cellspin I,
Tharmac GmbH, Waldsoms, Germany) and the neurospheres
were immunolabeled for Oligodendrocyte transcription factor 2
(Olig2), Glial fibrillary acidic protein (GFAP) and doublecortin
(DCX).
Cell-fate Studies: Sox2 Cell Pair Assay
Dissociated SVZ cell suspension obtained during the cell culture
procedure was plated on poly-D-lysine coated glass coverslips at a
density of 6400 cells/cm2. After seeding, SVZ cells were grown in
low EGF/FGF-2 containing medium supplemented or not
(control) with 1 mM R-m-AEA and/or 10 mM DAPT for 24 h.
Thereafter, cells were fixed in methanol for 15 min at 220uC and
then processed for immunocytochemistry against Sox2.
Immunocytochemistry
Cells were fixed for 30 minutes in 4% paraformaldehyde in
phosphate-buffered saline (PBS) or methanol, permeabilized and
blocked for non-specific binding sites for 1 h with 0.25% Triton
X-100 (Sigma-Aldrich) and 3% bovine serum albumin (BSA,
Sigma-Aldrich) dissolved in PBS. Cells were then subsequently
incubated overnight at 4uC with primary antibodies as listed in
Table 1 and for 1 h at RT with the appropriate secondary
antibodies as follows: donkey anti-mouse Alexa Fluor 594
antibody, anti-rabbit Alexa Fluor 488 or anti-goat Alexa Fluor
488 (all 1:200 and all from Invitrogen). Nuclei were visualized after
Hoechst 33342 incubation (6 mg/ml in PBS, Invitrogen). Finally,
the preparations were mounted using Dakocytomation fluorescent
medium (Dakocytomation, Carpinteria, CA, USA). Fluorescence
images were recorded using an Axioskop microscope (Carl Zeiss
Inc., Go¨ttingen, Germany) and confocal images were recorded
using a Zeiss LSM 510 META confocal microscope (Carl Zeiss
Inc., Go¨ttingen, Germany).
Cell Proliferation Studies
To investigate the effect of (R)-(+)-Methanandamide (R-m-AEA)
on cell proliferation, SVZ cells were exposed to 10 mM 5-bromo-
29-deoxyuridine (BrdU) (Sigma-Aldrich), a synthetic thymidine
analogue able to substitute thymidine in the DNA double chain
synthesis occurring in dividing cells, for the last 4 h of each R-m-
AEA (100 nM, 300 nM or 1 mM) treatment (48 h), as described
previously [30]. Then, SVZ cells were fixed in 4% PFA for 30 min
and rinsed with 0.15 M PBS at RT. Thereafter BrdU was
unmasked by permeabilizing cells in PBS 1% Triton X-100 at RT
for 30 min and DNA was denaturated in 1 M HCl for 40 min at
37uC. Following incubation in PBS with 0.5% Triton X-100 and
3% BSA to block nonspecific binding sites, cells were incubated
overnight with the anti-BrdU antibody (Table 1). After an
additional rinse in PBS, SVZ nuclei counterstaining and mounting
were performed as described previously.
Proliferation was also assessed using the Elisa BrdU colorimetric
assay (Roche, Basel, Switzerland). For that purpose, 40000 SVZ
cells obtained from dissociated primary neurospheres (Neurocult
dissociation kit) were plated per well of 96 well culture plates (4
wells per condition) and treated in the absence (control) or
presence of 1 mM R-m-AEA in SFM devoid of growth factors.
BrdU (10 mM) was added 4 h before the end of the 48 h lasting
culture session. Amount of BrdU incorporation was evaluated by
densitometry (at 450 nm) following the use of a peroxidase
conjugated anti-BrdU antibody and reaction with a peroxidase
substrate according to manufacturer’s instructions. As a positive
control, 10 ng/ml EGF together with 5 ng/ml FGF-2 was used.
Western Blotting Analysis
Western blotting analysis of CB1R, GFAP, Olig2 and phospho-
extracellular-signal-regulated kinase 1/2 (P-ERK1/2) was per-
formed from 6 day-old neurospheres that were plated into 6-well
plates previously coated with 0.1 mg/ml poly-D-lysine, and that
were allowed to adhere for 48 h in SFM before treatment or not
(control) with R-m-AEA (1 mM) for 15 min and 30 min (for P-
ERK) or 7 days (for CB1R, GFAP and Olig2). The cells were then
washed with 0.15 M PBS and harvested by scraping in lysis buffer
[0.15 M NaCl, 0.05 M Tris-base, 5 mM EGTA, 1% Triton X-
100, 0.5% Sodium deoxycholate (DOC), 0.1% SDS, 10 mM
dithiothreitol (DTT), containing a protease inhibitor cocktail tablet
(Roche), pH 7.4 at 4uC]. The supernatant was collected after
centrifugation at 14 000 rpm for 10 min, at 4uC. Protein
concentration was measured by the BCA method and samples
were treated with SDS-PAGE sample buffer [66 concentrated:
350 mM Tris, 10% (w/v) SDS, 30% (v/v) glycerol, 0.6 M DTT,
0.06% (w/v) bromophenol blue], boiled 5 min at 95uC, and stored
at 220uC until use for Western blotting analysis. Then, proteins
were separated by SDS-PAGE on 10% acrylamide/bisacrylamide
gels and transferred onto PVDF (polyvinylidine difluoride)
membranes with 0.45 mm pore size in the following conditions:
300 mA, 90 min at 4uC in a solution containing 10 mM CAPS
and 10% methanol, pH 11. Membranes were blocked and
incubated with the antibodies against CB1R (Proteimax, Cotia,
Brazil), GFAP (Cell Signaling Technology, Danvers, MA, USA),
Olig2 (Millipore, Billerica, MA, USA) or P-ERK1/2 (Cell
Signaling Technology). After washing, membranes were incubated
for 1 h at RT, with the respective alkaline phosphatase-linked
secondary antibodies. For endogenous control of immunolabeling,
PVDF membranes were reprobed with the antibodies against a-
Tubulin (Millipore) for CB1R, b-actin (Abcam, Cambridge, UK)
for GFAP and Olig2 and ERK1/2 (Cell Signaling Technology) for
P-ERK1/2. Then the membranes were incubated with the
alkaline phosphatase-linked secondary antibodies. Protein immu-
noreactive bands were visualized in a Versa-Doc Imaging System
fate. D: Confocal digital images of cell pairs obtained following (a) the symmetrical division of a SVZ cell into two Sox2+ cells (Sox2+/+), (b) the
asymmetrical division into a Sox2+ and a Sox2- progenitor (Sox2+/2) and (c) the symmetrical terminal division into two Sox2- progenitors (Sox22/2).
Scale bars 20 mm. E: Bar graph illustrates the number of each type of cell divisions counted. Data are expressed as the percentage of total cell pairs
and are represented as the mean 6 SEM. N= 5. *P,0.05 and ***P,0.001 using Bonferroni’s multiple comparison test, for comparison with the
respective controls; ###P,0.001 using Bonferroni’s multiple comparison test, for comparison with the respective R-m-AEA. SOX2: sex determining
region Y-box 2.
doi:10.1371/journal.pone.0063529.g002
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Figure 3. (R)-(+)-Methanandamide induces cell proliferation in SVZ cell cultures. A: Protocol used for studying cell proliferation. B: Bar
graph depicts the numbers of BrdU-positive cells expressed as percentage of the total number of cells. Data are expressed as mean 6 SEM. N=3–5.
**P,0.01 using Dunnett’s multiple comparison test, for comparison with control. C: Representative digital images of BrdU (red nuclei)-positive cells
and Hoechst 33342 staining (blue nuclei) in SVZ cultures. D: Amount of BrdU incorporation evaluated by densitometry (at 450 nm). N = 10. *P,0.05,
**P,0.01 and ***P,0.001 using Dunnnet’s multiple comparison test, for comparison with control; ##P,0.01 and ###P,0.001 using Dunnnet’s
multiple comparison test, for comparison with R-m-AEA; Scale bar = 50 mm.
doi:10.1371/journal.pone.0063529.g003
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(model 3000, BioRad Laboratories, CA), following incubation of
the membrane with ECF reagent (GE Healthcare, Buckingham-
shire, UK) for 5 min. Densitometric analyses were performed by
using the ImageQuant software (GE Healthcare Life Sciences).
Single Cell Calcium Imaging (SCCI)
To determine the functional differentiation pattern of SVZ cells,
the variations of [Ca2+]i in single cells following stimulation with
50 mM KCl (Merck; Darmstadt, Germany) and 100 mM hista-
mine (Sigma-Aldrich) were analyzed [31]. Histamine/KCl ratios
of peak values for Fura-2 were calculated to determine the extent
of neuronal differentiation in SVZ cultures (see Methods S1).
Statistical Analysis
Fluorescence digital images were recorded using an LSM
510 Meta confocal microscope or an Axioskop 2 Plus fluorescence
microscope (both from Carl Zeiss). In all experiments, measure-
ments were performed at the border of SVZ neurospheres where
migrating cells form a pseudo-monolayer of cells. For the self-
renewal assay, the experiments were replicated in six independent
culture preparations and each experimental condition was assayed
in four different wells. For the remaining experiments, each
condition was assayed in three different coverslips, and except
where otherwise specified, the experiments were replicated in
three independent culture preparations. For BrdU ELISA, each
experimental condition was reproduced in 4 different wells of a 96
well plate and experiments were assayed 4 times. Background
values obtained in the negative control wells were subtracted to all
values. Within each experiment, the mean of values of optical
density read at 450 nm in control wells were set to 100% and
optical densities of experimental conditions are expressed as
percentages of the Control condition. Number of neurospheres
that were immunoreactive for Olig2, Olig2/GFAP or Olig2/
GFAP/DCX was counted as a percentage of total neurospheres.
Percentages of Sox2 cell pairs were obtained from counting about
60 cell pairs in triplicate coverslips obtained from 3 independent
cultures. Percentages of BrdU, bIII tubulin/BrdU, NeuN/BrdU,
NeuN, VGAT, TH/bIII tubulin and GFP/MAP2 immunoreac-
tive cells were calculated from cell counts in five independent
microscopic fields in each coverslip with a 406 objective
(approximately 100 cells per field). Quantification of the number
of ramifications as well as total neurite length positive for MAP2
per MAP2/GFP cell was performed in 3 culture preparations in
approximately 20 non-overlapping fields per coverslip (406
magnification). Software used was Axiovision, release 4.6 (Carl
Zeiss).
For SCCI experiments, the percentage of neuronal-like
responding cells (with a Hist/KCl ratio below 0.8) was calculated
on the basis of one microscopic field per coverslip, containing
approximately 100 cells (406magnification), in a total of at least 3
independent cultures where each conditions are triplicate.
Figure 4. (R)-(+)-Methanandamide does not induce glial differentiation in SVZ cultures through CB1R activation. A: Protocol used for
studying glial differentiation. B:Western blot analysis of GFAP and Olig2 protein levels in SVZ. Data are expressed as mean6 SEM. N=4. C: Bar graph
depicts the number of GFAP and Olig2-positive cells, expressed as the percentage of total cells per culture. Data are expressed as mean6 SEM. N= 3.
D: Representative fluorescent digital images of GFAP-positive cells (green), Olig2-positive cells (red) and Hoechst staining (blue nuclei). Scale
bar = 50 mm.
doi:10.1371/journal.pone.0063529.g004
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Data are expressed as means 6 standard error of the mean (SEM).
Statistical significance was determined by using the unpaired two-
tailed Student’s t test or one-way analysis of variance followed by
Bonferroni or Dunnett’s-multiple comparison test, with p,0.05
considered to represent statistical significance.
Results
SVZ Cells Express CB1R
The expression of CB1R protein in SVZ-derived cells was
confirmed by western blotting (Fig. 1A) and immunocytochemistry
(Fig. 1B–E). In fact, CB1R was detected in immature nestin-
positive SVZ cells adhered on poly-D-lysine coverslips (Fig. 1B)
and in GFAP-positive astrocytes indicating that its expression is
also maintained in astrocytes (Fig. 1C, c1). We have also observed
the expression of CB1R in Sox2-positive single cells dissociated
from the SVZ during the cell culture procedure (Fig. S2).
Moreover, CB1R expression was detected in the neuronal lineage
since it was observed in neurons expressing PSA-NCAM (Fig. 1D),
bIII tubulin (Fig. 1E, e1) and MAP2 (Fig. 1F, f1).
(R)-(+)-Methanandamide Promotes Self-renewal and
Multipotency of SVZ Cell Cultures
Neural stem-like cells are characterized in vitro by both their
capacity to give rise to neurospheres and to self-renew when
cultured in the presence of mitogens [28]. Exposure of freshly
dissected SVZ cells to 1 mM R-m-AEA during 6 days did not
affect the number of primary neurospheres generated as compared
to control untreated cultures (control: 10062.46%; R-m-AEA
1 mM: 99.6766.37%; Fig. 2A, B). However, the number of
primary neurospheres was decreased when the cells were co-
treated with R-m-AEA together with an inhibitor of the Notch
pathway (DAPT) (R-m-AEA 1 mM+DAPT 10 mM:
58.9764.04%; DAPT 10 mM: 56.5366.09%, N=3; P,0.001).
On the other hand, a higher number of secondary neurospheres
was generated from SVZ cells derived from R-m-AEA treated cells
in comparison with control SVZ cultures (control: 100.062.47%;
R-m-AEA 1 mM: 125.965.42%; N=9, P,0.01; Fig. 2B), thus
indicating that R-m-AEA priming promoted SVZ cells capacity to
self-renew. This effect is lost with co-priming with 10 mM DAPT
(R-m-AEA 1 mM+DAPT 10 mM: 70.84614.54%, N=3,
P,0.001), while the inhibitor by itself also blocked the self-
renewal capacity (DAPT 10 mM: 47.58615.83%). These data
Figure 5. (R)-(+)-Methanandamide induces neuronal differentiation in SVZ cultures through CB1R activation. A: Schematic
representation of the protocol. B: Bar graph depicts the number of neuronal-like responding cells expressed as percentages of total cells analyzed by
SCCI. N = 4–8. *P,0.05, ***P,0.01 using Dunnett’s multiple comparison test, for comparison with control. C: Representative SCCI profiles of response
of about 20 cells in control, in R-m-AEA and in R-m-AEA+AM 251 treated cultures. D: Representative fluorescent digital images of NeuN-positive
neurons (red) and Hoechst staining (blue nuclei). Scale bar = 50 mm. E: Bar graph depicts the number of NeuN-positive cells, expressed as the
percentage of total cells per culture. Data are expressed as mean 6 SEM. N=5 ***P,0.001 using Dunnett’s multiple comparison test, for comparison
with control. SCCI: single cell calcium imaging; NeuN: Neuronal Nuclei.
doi:10.1371/journal.pone.0063529.g005
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suggest that the notch pathway mediates CB1R induction of self-
renewal.
The capacity of R-m-AEA to promote self-renewal of SVZ cells
was further tested by plating SVZ cells for 24 h in medium
complemented with R-m-AEA or control medium. After the
culture session, cells were stained for Sox2, a marker of neural
stem cells with the ability to self-renew (Fig. 2C). Cell pairs
resulting from the division of a single SVZ stem/progenitor cell
were counted and categorized in 3 groups according to their Sox2
expression: in both daughter cells (Sox2+/+), in only one of the
daughter cell (Sox2+/2) and no expression (Sox22/2) (Fig. 2D).
R-m-AEA at 1 mM induced a significant increase in the
percentage of Sox2+/+ cell pairs (control: 24.1261.67%; R-m-
AEA: 33.6162.42%; N=6, P,0.05) with a concomitant decrease
of Sox22/2 cell pairs as compared with controls (control:
50.5962.34%; R-m-AEA: 43.6463.31%; N=5) (Fig. 2E). These
data suggest that R-m-AEA induced self-renewing divisions.
Moreover, we observed that DAPT blocked the increase in
Sox2+/+ cell pairs (R-m-AEA 1 mM+DAPT 10 mM:
15.2362.85%), while promoting Sox22/2 cell pairs (R-m-AEA
1 mM+DAPT 10 mM: 65.363.78%), further suggesting that
CB1R role in self-renewal is dependent of the notch pathway.
Moreover, we evaluated if R-m-AEA exposure altered the
multipotency of the formed neurospheres, by adhering secondary
free-floating neurospheres to glass slides and analysing the
expression of Olig2, GFAP and DCX which are markers of
oligodendrocyte progenitors, astrocytes and neurons, respectively.
We observed an increased number of tripotent neurospheres
expressing simultaneously Olig2, GFAP and DCX (Control:
78.6362.95%; R-m-AEA 1 mM: 87.6362.84%; P,0.01, Fig.
S3), whereas the number of bipotent neurospheres expressing
Olig2 and GFAP was significantly reduced (Control:
20.6761.89%; R-m-AEA 1 mM: 11.7162.66%; N=3, P,0.05,
Fig. S3).
(R)-(+)-Methanandamide Stimulates Cell Proliferation
To determine whether R-m-AEA modulates cell proliferation,
increasing concentrations of R-m-AEA (100 nM, 300 nM, 1 mM)
were applied on SVZ cells in SFM devoid of growth factors, for
48 h (Fig. 3A). BrdU, an analog of the thymidine nucleotide, was
added during the last 4 h of the culture to label cells that went
through S-phase. After fixation, incorporated BrdU was immu-
nolabeled and positive nuclei were counted. A significant increase
in the number of BrdU-immunopositive nuclei was obtained in
cultures incubated with 1 mM but not with 100 nM or 300 nM,
when compared with control (control: 4.9760.35%; R-m-AEA
1 mM: 6.8760.541%; R-m-AEA 100 nM: 6.0160.54%; R-m-
AEA 300 nM: 5.6560.44%; N=3–5, P,0.01) (Fig. 3B). More-
over, the effect caused by R-m-AEA was blocked by the presence
of the CB1R antagonist AM 251 [R-m-AEA+AM
251:4.660.44%)], further indicating that R-m-AEA effect on cell
proliferation is CB1R-mediated (Fig. 3B). Furthermore, the effect
of R-m-AEA or AM 251 on cell viability was evaluated after 48 h
of drug treatment. Apoptotic nuclei were stained by the TUNEL
(Terminal deoxynucleotidyl transferase dUTP nick end labeling)
method and no significant differences in the number of TUNEL-
positive nuclei were found, indicating that none of the drugs were
toxic to the cells (control: 11.3861.14%; R-m-AEA 100 nM:
Figure 6. (R)-(+)-Methanandamide promotes proliferation of neuroblasts. A, D: Experimental protocol. B, E: Representative confocal digital
images of BrdU (red), bIII tubulin (green) and Hoechst staining (blue) (B) and of BrdU (red), NeuN (green) and Hoechst staining (blue) (E). Scale
bar = 20 mm. C, F: Bar graphs depict the number of bIII tubulin/BrdU-positive cells expressed as percentage of total bIII tubulin positive cells (C) and
NeuN/BrdU-positive cells expressed as percentage of total NeuN-positive cells (F) per culture. Data are expressed as mean 6 SEM. N= 3. *P,0.05,
**P,0.01 using unpaired Student’s t test for comparison with control. bIII tubulin: Neuron-specific class III beta-tubulin; NeuN: Neuronal Nuclei.
doi:10.1371/journal.pone.0063529.g006
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13.1262.04%; R-m-AEA 300 nM: 10.9761.07%; R-m-AEA
1 mM: 13.0862.33%; AM 251 1 mM: 13.360.76%; as a control,
culture medium containing 0.20% Ethanol: 12.6760.71%; N=3,
data not shown).
ERK1/2 is a mitogen-activated protein kinase (MAPK) known
to mediate proliferation of neuronal progenitor cells [32].
Moreover, it has been shown that PI3K/AKT pathway is also
involved in SVZ cell proliferation [33–35]. To investigate whether
the increase in cell proliferation mediated by R-m-AEA treatment
is dependent on ERK and/or PI3K/AKT pathways, we evaluated
proliferation by quantifying BrdU incorporation with an ELISA
detection method and used selective inhibitors of the signaling
pathways.
The increase in proliferation mediated by R-m-AEA was
blocked when cells were co-incubated with 20 mM U0126 a
MAPK kinase 1/2 inhibitor (MEK1/2) or with 25 mM LY294002,
a PI3K inhibitor, together with R-m-AEA (Control:
100.0061.06%; 1 mM R-m-AEA: 111.563.66%; 1 mM R-m-
AEA +20 mM U0126:92.2565.09%; 1 mM R-m-AEA +25 mM
LY294002:68.7365.72%; N=10) (Fig. 3D). These results sug-
gested a pro-proliferative action of CB1R activation involving
MAPK/ERK and AKT signaling pathways.
To investigate whether R-m-AEA activates the ERK1/2
signaling pathway, SVZ cell cultures were exposed to 1 mM R-
m-AEA for 15 min and 30 min and cells were processed for
western blotting to detect phosphorylated activated form of
ERK1/2 (P-ERK1/2). We observed that P-ERK1/2 protein
levels increased to 138.4612.12% (N=5, P,0.05) in cultures
exposed for 15 min to R-m-AEA when comparing with control
condition (set to 100%) (Fig. S4).
(R)-(+)-Methanandamide Induces Neuronal
Differentiation via CB1R Activation
The effects of R-m-AEA on glial cell differentiation were
assessed by western blotting from SVZ cells treated with R-m-AEA
for 7 days. Quantification of GFAP and Olig2 protein levels was
performed and we found no effect of R-m-AEA treatment (GFAP:
control set at 100%, R-m-AEA 1 mM: 102.965.90%; Olig2:
control set at 100%, R-m-AEA 1 mM: 94.2864.57%, N=4),
indicating that R-m-AEA does not affect glial differentiation
(Fig. 4B). Moreover, we performed immunocytochemistry against
GFAP and Olig2 in SVZ cultures incubated for 7 days in the
absence (control) or presence of 1 mM R-m-AEA. No differences
in the numbers of astrocytes and oligodendrocytes were observed
between the conditions (GFAP, control: 20.3860.98%, R-m-AEA:
18.8360.81%; Olig-2, control: 8.2560.8%, R-m-AEA:
9.1560.69%; N=3) (Fig. 4C,D).
We next investigated whether R-m-AEA affected neuronal
differentiation. For that purpose, SVZ cells were treated with R-
m-AEA for 7 days (Fig. 5A). To functionally evaluate neuronal
differentiation in SVZ cultures, we used a method previously
described by us [26,31,36]. For that we analysed the variations of
[Ca2+]i at single cell level upon KCl and histamine (Hist)
stimulations, Hist/KCl ratios below 0.8 being characteristic of
SVZ-derived neuronal-like cells [31]. In control cultures we
observed a predominant immature-like profile, characterized by
an increase in [Ca2+]i in response to histamine but a small
response or no response to KCl stimulation (Fig. 5C). Interestingly,
the majority of R-m-AEA treated SVZ cells displayed an increase
in [Ca2+]i in response to KCl but not to histamine stimulation,
consistent with a neuronal-like profile (Fig. 5C). Quantification of
the percentage of cells displaying a Hist/KCl ratio below 0.8
showed that R-m-AEA is proneurogenic (Control: 12.1862.09%;
Figure 7. (R)-(+)-Methanandamide promotes the expression of the proneurogenic genes Ngn1. A: Scheme of the protocol. B: Bar graph
depicts the fold increase of H3K36m3 recruitment in the promoter region of Ngn1 gene quantified by qChIP analysis. C: Bar graph depicts the fold
increase of mRNA expression for Ngn1 protein evaluated by qRT-PCR analysis. Data are expressed as mean6 SEM. N=4–7. *P,0.05, using Dunnett’s
test for comparison with control (set to 1). H3K36m3: Histone H3 trimethylated on lysine 36; Ngn1: Neurogenin 1; qChIP: quantitative chromatin
immunoprecipitation; qRT-PCR: quantitative real time polymerase chain reaction.
doi:10.1371/journal.pone.0063529.g007
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R-m-AEA 100 nM: 26.5464.28%, P,0.05; R-m-AEA 300 nM:
34.5866.0%, P,0.001; R-m-AEA 1 mM: 41.5264.49%,
P,0.001; N= 4–8; Fig. 5B). Moreover, we observed that the
CB1R antagonist AM 251 (1 mM) was capable of blocking R-m-
AEA-induced neuronal differentiation [R-m-AEA 1 mM+AM 251
1 mM: 8.2964.27%; AM 251 1 mM: 13.8863.00%; N=4,
Fig. 5B)]. This method allowed us to quantify glial cells as these
cells do not respond to KCl nor to histamine and thereby display a
ratio of response close to 1 [31]. No differences were obtained
between the conditions (Fig. S5A) further attesting that CB1R
stimulation does not affect glial differentiation (ratio Hist/KCl
0.9–1) (Control: 38.3763.45%: R-m-AEA 100 nM:
35.9563.47%; R-m-AEA 300 nM: 29.6863.70%; R-m-AEA
1 mM: 30.7564.61%, N=8). Moreover, we also observed that
CB1R activation promoted a decrease in the % of immature-like
cells (ratio Hist/KCl 1–1.3) (Control: 26.2263.28%; R-m-AEA
100 nM: 10.5262.39%; R-m-AEA 300 nM: 11.8263.03%; R-m-
AEA 1 mM: 9.4961.50%, N=8) (Fig. S5B). Further supporting
the role of CB1R activation in neuronal differentiation, R-m-AEA
induced an increase in NeuN-positive cells when compared with
control cultures (Control: 5.3560.53%; R-m-AEA 1 mM:
11.3361.05%; N=4–5, P,0.001), and CB1R antagonist blocked
this effect (R-m-AEA 1 mM+AM 251 1 mM: 4.6660.73%)
(Fig. 5D, E), further suggesting that R-m-AEA promotes neuronal
differentiation. Additionally, we also found that the treatment with
R-m-AEA increased proliferation of neuronal progenitors, as
observed by the increase in bIII tubulin/BrdU-positive cells in
SVZ cultures treated with R-m-AEA for 48 h (Control:
6.0160.68%; 1 mM R-m-AEA: 9.8761.16%; N=3, P,0.05)
(Fig. 6A,B,C), without affecting the total number of bIII tubulin-
positive cells (Control: 27.061.39%; 1 mM R-m-AEA:
26.1562.01%; N=3, data not shown). Using a pulse of BrdU
together with R-m-AEA for the first 24 h of treatment followed by
a chase of 6 days (without BrdU) in the absence (control) or in the
presence of R-m-AEA (Fig. 6D) we observed an increase in the
number of NeuN/BrdU-positive cells in the treated condition as
compared to control, indicating that R-m-AEA may interfere in
the early stages of neuronal differentiation, committing progenitors
towards a neuronal fate (Control: 5.3160.99%; 1 mM R-m-AEA:
15.2462.43%; N=3, P,0.01) (Fig. 6 E, F).
To disclose if R-m-AEA has proneurogenic effects through
histone modifications associated with the transcription of the
proneurogenic gene Ngn1, we performed qChIP targeting the
trimethylated lysine 36 of the H3 histone (H3K36m3) followed by
Figure 8. (R)-(+)-Methanandamide induces the differentiation of GABAergic neurons and neuritogenesis. A: Schematic representation
of the protocol. B: Bar graph depicts the numbers of either VGAT- or TH/bIII tubulin-positive cells, expressed as percentage of total cells. The data are
expressed as percentage 6 SEM. N= 3. *P,0.05 using unpaired Student’s t test for comparison with control. C: Schematic representation of the
protocol used for studying neuritogenesis. D: Representative confocal digital images of the GFP (green), MAP2 (red), Hoechst staining (blue), in
control cultures and in cultures exposed to R-m-AEA. Scale bar = 20 mm. E: Bar graphs depict (from left to right): total length (mm), number of primary
and number of secondary ramifications of MAP2 neurites per cell. N = 3. **P,0.01 using unpaired student’s t test for comparison with control. MAP2:
Microtubule-associated protein 2; TH: tyrosine hydroxylase; bIII tubulin: Neuron-specific class III beta-tubulin; VGAT: vesicular GABA transporter.
doi:10.1371/journal.pone.0063529.g008
Type 1 Cannabinoid Receptors in SVZ Neurogenesis
PLOS ONE | www.plosone.org 11 May 2013 | Volume 8 | Issue 5 | e63529
a qPCR analysis (Fig. 7A). This specific histone methylation is
associated with transcription-active euchromatin [37], therefore
lineage potential can be studied by observing histone methylation
associated with the transcription of a proneurogenic gene. We
observed an early increased recruitment of H3K36m3 to the
regulatory elements of Ngn1 in SVZ cells exposed to 1 mM (R)-(+)-
Methanandamide, for 6 h (5.0063.06; control set to 1, N=3),
suggesting the enhancement of the transcriptional activity of Ngn1
(Fig. 7B). Using qRT-PCR analysis, we confirmed that 1 mM R-
m-AEA triggered a significant increase in Ngn1 mRNA levels
(2.7760.697 fold increase; N= 4, P,0.05) in SVZ cells treated for
3 days as compared with controls (set to 1) (Fig. 7C).
We then investigated whether 1 mM R-m-AEA influences the
phenotype of the neuronal cells produced in the cultures. For that
purpose immunolabelings for the vesicular GABA transporter
(VGAT) and the tyrosine hydroxylase (TH) were performed on
7 day-treated cultures since GABAergic and dopaminergic neu-
rons are the two major phenotypes of SVZ-derived neurons
(Fig. 8A). We observed an increase in VGAT-positive cells
(Control: 13.5762.29%; R-m-AEA: 20.5261.76%; N=3,
P,0.05), while, in the same experimental conditions, we did not
observed an increase in TH-positive cells (Control: 11.3461.38%;
R-m-AEA: 12.0461.55%) (Fig. 8B). Finally, consistently with the
observed proneurogenic action of endocannabinoids, we investi-
gated whether the R-m-AEA triggered the growth of neurites. For
that we exposed mixed cultures of WT and GFP mice for 7 days to
1 mM R-m-AEA and we evaluated the length and the number of
primary and secondary ramifications of MAP2 positive neurites
(Fig. 8C, D). Exposure of SVZ cells to R-m-AEA induced a
marked increase in the length of MAP2/GFP-positive neurites per
cell (Control: 29.062.14 mm; 1 mM R-m-AEA: 45.4163.96 mm;
N=3, P,0.01) (Fig. 8E). However, the number of primary and
secondary ramifications of MAP2/GFP-positive treated cells was
similar to control cultures (Fig. 8E).
Discussion
The role of endocannabinoids in the regulation of neurogenesis
has been the subject of several recent studies; however most of
these studies address the effects of endocannabinoids on hippo-
campal neurogenesis with emphasis on proliferation. Here we
examined the effects of endocannabinoids on SVZ-derived cells,
given that SVZ represents the main stem cell reservoir in the
rodent adult brain. These cells may be used for cell replacement
therapies if efficient proneurogenic compounds are identified. In
our study, we disclosed the modulatory effects of endocannabi-
noids on SVZ proliferation, cell fate decision, survival and
differentiation.
Firstly, we observed by western blotting that CB1R is expressed
in SVZ cell cultures. CB1R is indeed expressed in immature
nestin-positive cells (marker of stem-like cells in vitro), in astrocytes
(GFAP-positive cells) and in immature neurons (PSA-NCAM- and
DCX-positive cells). Others have shown that neural progenitor
cells express CB1R, in fact CB1R was found to be expressed in vivo
in the SVZ and DG and in nestin-positive cells from neural
progenitor cultures [17,20,21,38].
We have also found that R-m-AEA promotes self-renewal and
multipotency of SVZ cell cultures, as observed by an increase in
the total number of secondary neurospheres that were also
tripotent (Olig2/GFAP/DCX). Moreover, CB1R agonist treat-
ment induced self-renewing divisions, resulting in an increased
number of Sox2+/+ pairs of daughter cells. Accordingly, these
data indicate that CB1R activation promotes stemness in SVZ
cells. To our knowledge, this is the first time that such a property
for CB1R activation is directly demonstrated, although it was
already suggested that CB1R activation might be important to
maintain self-renewal of embryonic cortical neural stem cells
cultures in proliferation conditions [39]. Recently, Compagnucci
and collaborators [40] have shown by gene array profiling that in
embryonic mice cortical neural stem cells under differentiation
conditions (no growth factor, 1% serum and upon adherence),
CB1R activation increases the expression of genes involved in
neuronal differentiation while it decreased the genes involved in
stemness. However, we herein studied the role of CB1R in stemnes
in the postnatal neural stem cells under proliferation conditions. In
concordance with their results the number of immature cells in our
cultures, evaluated according to their response to histamine but
not to KCl [31], decreased with R-m-AEA treatment under
differentiation conditions. In addition, we observed that inhibiting
the Notch pathway with DAPT blocked the increase in self-
renewal induced by R-m-AEA treatment, suggesting that the
notch pathway mediates CB1R induction of self-renewal. In fact,
Tanveer and collaborators [41] have shown that anandamide,
increases Notch-1 signaling in cortical neurons exposed to
amyloid-beta and in the cortex of aged rats.
Moreover, we observed an increase in the number of BrdU-
positive cells in cultures treated with R-m-AEA, and this effect was
blocked by a CB1R selective antagonist, further showing that R-
m-AEA effect is CB1R-mediated. In fact, there is an emerging
consensus that endocannabinoid signaling plays a major role in
proliferation. In this context, reduction in neural stem cell
proliferation was seen in both the hippocampus and SVZ in
CB1R-KO animals [21,22,38] and in diacylglycerol lipase
(DAGL, the enzyme that synthesize 2-AG, one of the main
endocannabinoids in the CNS)-KO mice [18]. Accordingly,
knocking-out or inhibiting the enzyme fatty acid amide hydrolase
(FAAH, an enzyme involved in the breakdown of endocannabi-
noids), promotes the increase in proliferation [17,38]. Further-
more, several data also suggest that CB1R activation induces
proliferation [17,20,24]. However, other reports also suggest that
CB2R are expressed by neural stem cells, and that CB2R-selective
agonists and antagonists modulate the generation of cultured
neural stem cell and precursor cell proliferation [19,42–44]. We
found that incubation of SVZ stem/progenitor cell cultures with
R-m-AEA together with U0126 (an inhibitor of ERK pathway) or
with LY294002 (an inhibitor of PI3K pathway) promotes a
decrease in BrdU incorporation, when comparing with CB1R
agonist treatment alone, demonstrating that these pathways (ERK
and PI3K) play pivotal roles in the CB1R-dependent modulation
of proliferation.
In fact, others have already shown that ERK and PI3K
pathways are important regulators of CB1R-mediated prolifera-
tion [13,20,45]. Most of the studies claiming that CB1R activation
promotes neurogenesis addressed their role in proliferation rather
than in cell differentiation. Therefore, we studied the effect of R-
m-AEA treatment, in differentiation conditions, on glial and
neuronal differentiation. We observed that CB1R activation did
not induce differentiation of GFAP-positive astrocytes or Olig2-
positive oligodendrocytes. However, previous published results are
apparently discordant because some authors have shown that
endocannabinoid treatment promotes astroglial and/or oligoden-
droglial differentiation [38,41,46,47] while others have shown that
CB1R activation promotes neuronal differentiation [40,48]. Our
results are in accordance with an effect mediated by CB1R
activation on neuronal differentiation. In fact, we found that R-m-
AEA induces functional neuronal differentiation in SVZ cell
cultures via CB1R activation and these results were further
supported by an increase in the number of NeuN-positive cells.
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We also found that treatment with R-m-AEA increased prolifer-
ation of neuronal progenitors (bIII tubulin/BrdU-positive cells) in
48h treated cultures. Interestingly, the total number of bIII
tubulin-positive cells was similar between the control and R-m-
AEA treated condition, for 48 h. However after 7 days of
treatment, the proportion of NeuN-positive cells was increased.
R-m-AEA may increase neuronal differentiation via promoting
proliferation of neuronal precursor cells, but also by accelerating
neuronal maturation. Indeed, more progenitor cells labeled with
BrdU, for the first 24 h of the culture session, ultimately
differentiated into NeuN-positive mature neurons following 7 days
of treatment with R-m-AEA. Moreover, we showed that
GABAergic differentiation is favored by R-m-AEA treatment.
Soltys and collaborators have also observed an increase in
neuronal differentiation of neural progenitor cells by anadamide
treatment [48]. However, Rueda and collaborators [49] showed
that endocannabinoids and the CB1R agonist HU210 inhibited
neuronal progenitor cell differentiation through a reduction of the
ERK pathway activation in cultured embryonic cortical cells,
human neural stem/progenitor cells and PC12 cells stably
transfected with human CB1R. In addition, endocannabinoid
signaling has been shown to promote astroglial differentiation of
cortical neural progenitor cells and of adult hippocampal
progenitors [38]. The divergent effects shown in the bibliography
concerning the role of endocannabinoids on neurogenesis may
partly rely on the use of different pharmacologic approaches. In
fact, the cannabinoids may have different affinity for CB1R,
CB2R, and also Transient Receptor Potential Vanilloid receptor 1
(TRPV1) [50], which may account for the observed differences.
Moreover, these discrepancies can also be explained by differences
in the study design, compounds used and gender of the animals
[22]. Besides, the readout parameters for adult neurogenesis vary
between studies with some reports focusing only on the effects of
CB1R on proliferation [20,21].
Emerging information indicates that epigenetic alterations
comprising histone modifications and chromatin remodeling
may be inherent to the maintenance and differentiation of neural
stem cells. However, their involvement has not yet been
completely understood. Recent studies indicate that lineage
control genes, such as Ngn1, are epigenetically modified with a
unique combination of histone modifications that prime them for
potential activation upon cell lineage induction and differentiation
[51]. Here we investigated whether R-m-AEA could promote
H3K36m3 modification in the promoter region of Ngn1, since this
is considered to be a proneurogenic gene [52]. Accordingly, upon
R-m-AEA treatment, we observed an increase of H3K36m3 on
Ngn1 promoter region, which ultimately lead to an increased
mRNA expression of this proneurogenic gene. Importantly, recent
reports have shown that Ngn1 is able to commit pluripotent
embryonic carcinoma P19 cells to adopt a neural cell phenotype
[53,54]. Moreover, we have recently shown that histamine
promotes neurogenesis and that this proneurogenic effect involves
epigenetic modifications and increased expression of Mash1, Dlx2,
and Ngn1 genes [55].
The differentiation process in neurons is a complex phenom-
enon involving multiple changes in electrophysiological charac-
teristics as well as changes in morphology characterized by neurite
(dendritic and axonal) outgrowths. Regulation of neurite out-
growth is tightly controlled and many neurotransmitters are
involved in this process [56]. Therefore, we studied neuritogenesis
and we observed that primary ramification length was significantly
higher in R-m-AEA-treated cultures, showing that CB1R
promotes neuronal maturation. Also, Jordan and collaborators
have shown that CB1R activation induces neurite outgrowth in
Neuro-2A cells [56]. Moreover, recent findings in both mammals
[57] and non-mammalian vertebrates [58] suggest that CB1R
activation is required for axonal elongation and fasciculation. In
addition, Mulder and collaborators [59] have shown that CB1R
activation drives neural progenitors proliferation and migration
and that in immature pyramidal cells, CB1R activation is required
for axonal polarization and for the formation of long-range
glutamatergic axons. More recently, it was shown that CB1R
activation promotes neuronal maturation from embryonic neural
stem cells in differentiation conditions [40].
Taken together, our results further dissect the role of CB1R on
SVZ neurogenesis and demonstrate that its activation promotes
self-renewal, proliferation, neuronal differentiation and matura-
tion.
Supporting Information
Figure S1 Neurospheres are composed by stem/pro-
genitor cells. Representative confocal digital image depicting
Sox2 and Nestin immunoreactivity in a SVZ neurosphere [Sox2
(in red), nestin (in green) Hoechst 33342 (used to visualize cell
nuclei, in blue)]. Scale bar = 20 mm
(TIF)
Figure S2 CB1R is expressed in stem/progenitor cells.
Representative confocal digital image depicting Sox2 and CB1R
immunoreactivity in SVZ cells plated for 24h after culture
procedure. Scale bar = 20 mm
(TIF)
Figure S3 (R)-(+)-Methanandamide promotes multipo-
tency. Bar graphs depict the number of secondary neurospheres
expressing either Olig2, Olig2/GFAP or Olig2/GFAP/DCX.
Numbers are expressed as percentage of total spheres counted.
N= 3. *P,0.05 and **P,0.01 using Bonferroni’s multiple
comparison test, for comparison with the respective controls.
Olig2: Oligodendrocyte transcription factor 2; GFAP: Glial
fibrillary acidic protein; DCX: Doublecortin.
(TIF)
Figure S4 (R)-(+)-Methanandamide activates ERK path-
way. Graph depicts the percentages relative to control of P-
ERK1/2 protein levels normalized to total ERK1/2 in SVZ
cultures. Below the graph, a representative Western blot for 44/
42 kDa P-ERK and ERK is shown. N= 5. *P,0.05 using
Bonferroni’s multiple comparison test for comparison with the
respective controls
(TIF)
Figure S5 (R)-(+)-Methanandamide does not induce
glial differentiation in SVZ cultures through CB1R
activation. A: Bar graph depicts the number of glial-like (A)
and immature-like (B) responding cells expressed as percentages of
total cells analyzed by SCCI. N=8. **P,0.01 and ***P,0.01
using Dunnett’s multiple comparison test, for comparison with
control.
(TIF)
Methods S1 Detailed description of methods for: a) SVZ
cell cultures; b) single-cell calcium imaging (SCCI); c)
quantitative chromatin immunoprecipitation (qChIP);
d) cDNA synthesis and realtime RT-PCR analysis
(Ngn1).
(DOC)
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